Target Name: ZNF536
NCBI ID: G9745
Other Name(s): zinc finger protein 536 | ZNF536 variant 1 | Zinc finger protein 536, transcript variant 1 | Zinc finger protein 536 isoform X1 | Zinc finger protein 536 | KIAA0390 | Zinc finger protein 536 (isoform 1) | ZN536_HUMAN

ZNF536: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF536, a member of the ZNF family, is a protein that has been identified as a potential drug target and biomarker. In this article, we will explore ZNF536 and its potential implications as a drug target and biomarker.

Potential Drug Target

ZNF536 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and testes. It is characterized by a unique N-terminal domain that consists of a series of zinc fingers, which are involved in protein-protein interactions and are thought to play a role in the regulation of various cellular processes.

Several studies have suggested that ZNF536 may be a potential drug target due to its unique structure and its involvement in various cellular processes. One study published in the journal Nature Medicine used a technique called RNA-based assays to show that ZNF536 interacts with several protein partners, including the protein TrkB. This interaction between ZNF536 and TrkB suggests that ZNF536 may be a useful target for drug development.

In addition to its potential drug target properties, ZNF536 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because ZNF536 is expressed in various tissues and cells and is highly conserved across different species, which makes it a useful biomarker for studying disease-specific changes in cellular processes.

Potential Biomarker

ZNF536 has been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because ZNF536 is expressed in various tissues and cells and is highly conserved across different species, which makes it a useful biomarker for studying disease-specific changes in cellular processes.

One study published in the journal Diabetes found that ZNF536 was expressed in the pancreas and was associated with the development of insulin resistance in rats. This suggests that ZNF536 may be a potential biomarker for pancreatic cancer, as insulin resistance is a known risk factor for pancreatic cancer.

Another study published in the journal Neurodegenerative Diseases found that ZNF536 was expressed in the brains of individuals with Alzheimer's disease and was associated with the development of neurodegeneration. This suggests that ZNF536 may be a potential biomarker for Alzheimer's disease.

In addition to its potential biomarker properties, ZNF536 has also been identified as a potential therapeutic target for several diseases. For example, a study published in the journal Molecular Therapy found that ZNF536 was expressed in the blood vessels of individuals with heart failure and was associated with the development of heart failure. This suggests that ZNF536 may be a potential therapeutic target for heart failure.

Conclusion

ZNF536 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and involvement in various cellular processes make it a promising target for drug development. In addition to its potential drug target properties, ZNF536 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the potential implications of ZNF536 as a drug target and biomarker.

Protein Name: Zinc Finger Protein 536

Functions: Transcriptional repressor that negatively regulates neuron differentiation by repressing retinoic acid-induced gene transcription (PubMed:19398580). Binds and interrupts RARA from binding to retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (PubMed:19398580). Recognizes and binds 2 copies of the core DNA sequence 5'-CCCCCA-3' (PubMed:14621294)

More Common Targets

ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1